Ximelagatran

Ximelagatran

Clinical data
Pregnancy category	uncategorised
Routes of administration	Oral
ATC code	B01AE05 (WHO)
Legal status
Legal status	Rx only/POM
Pharmacokinetic data
Bioavailability	20%
Metabolism	None
Elimination half-life	3-5h
Excretion	Renal (80%)
Identifiers
IUPAC name ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate
CAS Number	192939-46-1
PubChem CID	5478933
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H35N5O5
Molar mass	474 (429 after conversion)

WikiDoc Resources for Ximelagatran
Articles
Most recent articles on Ximelagatran Most cited articles on Ximelagatran Review articles on Ximelagatran Articles on Ximelagatran in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ximelagatran Images of Ximelagatran Photos of Ximelagatran Podcasts & MP3s on Ximelagatran Videos on Ximelagatran
Evidence Based Medicine
Cochrane Collaboration on Ximelagatran Bandolier on Ximelagatran TRIP on Ximelagatran
Clinical Trials
Ongoing Trials on Ximelagatran at Clinical Trials.gov Trial results on Ximelagatran Clinical Trials on Ximelagatran at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ximelagatran NICE Guidance on Ximelagatran NHS PRODIGY Guidance FDA on Ximelagatran CDC on Ximelagatran
Books
Books on Ximelagatran
News
Ximelagatran in the news Be alerted to news on Ximelagatran News trends on Ximelagatran
Commentary
Blogs on Ximelagatran
Definitions
Definitions of Ximelagatran
Patient Resources / Community
Patient resources on Ximelagatran Discussion groups on Ximelagatran Patient Handouts on Ximelagatran Directions to Hospitals Treating Ximelagatran Risk calculators and risk factors for Ximelagatran
Healthcare Provider Resources
Symptoms of Ximelagatran Causes & Risk Factors for Ximelagatran Diagnostic studies for Ximelagatran Treatment of Ximelagatran
Continuing Medical Education (CME)
CME Programs on Ximelagatran
International
Ximelagatran en Espanol Ximelagatran en Francais
Business
Ximelagatran in the Marketplace Patents on Ximelagatran
Experimental / Informatics
List of terms related to Ximelagatran

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ximelagatran (Exanta® or Exarta®, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.

Method of action

Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. It acts solely by inhibiting the actions of thrombin. It is taken orally twice daily, and rapidly absorbed by the small intestine. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen).

Uses

Ximelagatran was expected to replace warfarin and sometimes aspirin and heparin in many therapeutic settings, including deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation such as stroke. The efficacy of ximelagatran for these indications had been well-documented (Eriksson et al 2003, Frances et al 2004, Schulman et al 2004).

An advantage, according to early reports by its manufacturer, was that it could be taken orally without any monitoring of its anticoagulant properties. This would have set it apart from warfarin and heparin, which require monitoring of the international normalized ratio (INR) and the partial thromboplastin time (PTT), respectively. A disadvantage recognised early was the absence of an antidote in case acute bleeding develops, while warfarin can be antagonised by vitamin K and heparin by protamine sulfate.

Side-effects

Ximelagatran was generally well tolerated in the trial populations, but a small proportion (5-6%) developed elevated liver enzyme levels, which prompted the FDA to reject an initial application for approval in 2004. The further development was discontinued in 2006 after it turned out hepatic damage could develop in the period subsequent to withdrawal of the drug. According to AstraZeneca, a chemically different but pharmacologically similar substance, AZD0837, is undergoing testing for similar indications (AstraZeneca press release 2006).

References

• "AstraZeneca Decides to Withdraw Exanta" (Press release). AstraZeneca. February 14, 2006.
• Eriksson, H (2003). "A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I". Journal of Thrombosis and Haemostasis. 1: 41&ndash, 47. PMID 12871538.
• Francis, CW (2003). "Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement". New England Journal of Medicine. 349 (18): 1703&ndash, 1712. PMID 14585938.
• Schulman, S (2003). "Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran". New England Journal of Medicine. 349 (18): 1713&ndash, 1721. PMID 14585939.
• Weitz, JI (2004). "New anticoagulants for treatment of venous thromboembolism". Circulation. 110 (Suppl 1): 19&ndash, 26. PMID 15339877.